PROCEPT BioRobotics (NASDAQ: PRCT) recently announced FDA 510(k) clearance of its next-generation platform, the HYDROS Robotic System. This clearance marks an important achievement for PROCEPT BioRobotics as Aquablation therapy continues its rapid adoption, with more than 400 robotic systems now installed across the United States. HYDROS Robotic System presents major technological innovations intended for broad market adoption after years of research and development, which the company expects to drive the next stage of its growth. More on the HYDROS Robotic SystemAquablation therapy is a minim…